Peptides for Weight Loss: GLP-1, GIP, and Amylin in Research Comparison

Peptides for weight loss are, in research terms, a class of receptor agonists that produce a dose-dependent reduction in body weight in animal models and clinical trials. The three most intensively studied mechanisms are GLP-1, GIP, and amylin receptor agonism, exemplified by retatrutide, tirzepatide, semaglutide, and cagrilintide. This guide places the evidence in neutral context, strictly as a research comparison and without any statement regarding human use.

What does "peptides for weight loss" mean in research?

In a scientific context, the term "peptides for weight loss" describes synthetic peptide analogues of the body's own incretin and satiety hormones, used as research compounds to study energy balance and obesity models. The relevant receptor classes are GLP-1 (Glucagon-like Peptide-1), GIP (Glucose-dependent Insulinotropic Polypeptide), the glucagon receptor (GCG-R), and the amylin receptor. In preclinical and clinical studies, these receptors are targeted individually or in combination.

Retatrutide (research code LY3437943) is a triple agonist that binds GIP, GLP-1, and glucagon simultaneously, setting it apart from the dual GIP/GLP-1 agonist tirzepatide and the GLP-1 mono-agonist semaglutide. In the Phase 2 trial by Jastreboff et al., 2023, the authors reported a dose-dependent weight reduction of up to -24.2 percent at 48 weeks versus -2.1 percent on placebo across n=338 trial participants.

All substances named in this guide are research peptides. The data derive from controlled clinical trials on the respective drug candidates and describe only the pharmacological characterization of these molecules, not their use outside the trial context. A deeper overview is available in the Retatrutide guide and the Tirzepatide guide.

How do GLP-1 peptides for weight loss work in research?

GLP-1 peptides for weight loss act in research through the GLP-1 receptor, which is involved in regulating satiety, gastric emptying, and glucose-dependent insulin secretion. GLP-1 mono-agonism is regarded as the longest-studied principle in this substance class and serves as a reference point for all newer multi-receptor molecules.

Semaglutide 2.4 mg is the prototypical GLP-1 mono-agonist. In the Phase 3 trial STEP 1 by Wilding et al., 2021, the authors reported a mean weight change of -14.9 percent versus -2.4 percent on placebo at 68 weeks across n=1961 trial participants; 86 percent of the active group achieved a reduction of at least 5 percent in this model.

The underlying mechanism rests on delayed gastric emptying and central nervous modulation of the satiety signal. Because insulin secretion is triggered in a glucose-dependent manner, the hypoglycemia risk remains low in the preclinical characterization. From this reference profile, research derives the question of whether additional activation of GIP, glucagon, or amylin receptors produces additive effects on energy balance. This precise question sits at the center of multi-agonist development, addressed in the sections that follow. A direct data comparison of two multi-agonists is available at Retatrutide vs. Tirzepatide.

What role does GIP play alongside GLP-1 in research?

The GIP receptor is the second incretin target protein and is closely linked to the GLP-1 pathway in research. GIP modulates insulin secretion and additionally acts on adipose tissue and central nervous circuits involved in food intake. The combination of GIP and GLP-1 agonism forms the pharmacological foundation of the dual agonists.

Tirzepatide is the prototypical dual GIP/GLP-1 agonist. In the Phase 3 trial SURMOUNT-1 by Jastreboff et al., 2022, the authors reported a mean weight reduction of 16.0 percent (5 mg) to roughly 22.5 percent (15 mg) versus about 3.1 percent on placebo at 72 weeks across n=2539 trial participants. Notable is the composition of the weight loss: fat-mass reduction was roughly three times greater than the reduction in lean mass (33.9 percent versus 10.9 percent).

In the dual model, the GIP component reinforces the appetite-regulating effect and additionally influences insulin sensitivity. The share of participants achieving a reduction of at least 25 percent rose with dose to as much as 39.7 percent versus 0.3 percent on placebo. These data make dual agonism the bridge between classical GLP-1 mono-agonism and triple agonism, which adds a third receptor.

What makes glucagon-receptor agonism special in retatrutide?

Retatrutide differs from all dual and mono-agonists through additional activation of the glucagon receptor (GCG-R). While GIP and GLP-1 primarily modulate insulin secretion and satiety, the glucagon component addresses energy turnover: in the preclinical characterization by Coskun et al., 2022, an increase in basal energy expenditure and elevated hepatic lipid oxidation were described, meaning increased metabolism of liver fat.

This triple receptor action is reflected in the clinical data. In the Phase 2 trial by Jastreboff et al., 2023, the authors reported graded weight reductions of -8.7 percent (1 mg), -17.1 percent (4 mg), -22.8 percent (8 mg), and -24.2 percent (12 mg) versus -2.1 percent on placebo. Particularly striking was the liver-fat reduction of roughly 86 percent in the 12 mg group, with 93 percent of these participants reaching normal liver-fat levels at 48 weeks (Sanyal et al., 2024), a finding of high interest for NAFLD and NASH research.

The compound is supplied as lyophilized powder with a purity of at least 99 percent (HPLC), mass-spectrometry confirmed and endotoxin tested.

These trial results relate exclusively to the drug candidate under clinical investigation; they are not a promise of benefit and not a reason to buy.

Order Retatrutide now

Further structured data comparisons are offered at Retatrutide vs. Tesamorelin and Retatrutide vs. MOTS-c.

How does an amylin analogue perform in weight loss?

An amylin analogue addresses a weight-loss pathway independent of GLP-1 and GIP: the amylin receptor, which mediates satiety and gastric emptying through its own central nervous pathways. The research representative of this class is cagrilintide, a long-acting amylin analogue. The decisive scientific question is whether the amylin and GLP-1 pathways behave additively.

This question was first answered by the Phase 1b trial of Enebo et al., 2021. Across n=95 trial participants, the authors reported over 20 weeks a weight reduction of -15.7 percent (cagrilintide 1.2 mg) and -17.1 percent (cagrilintide 2.4 mg) in combination with semaglutide 2.4 mg, compared with -9.8 percent on semaglutide alone. This was the first human evidence that amylin and GLP-1 act additively.

The fixed combination CagriSema was subsequently studied in larger trials. The Phase 3 trial REDEFINE 1 (Garvey et al., 2025) reported a reduction of -20.4 percent versus -3.0 percent on placebo at 68 weeks across n=3417 participants. Complementing this, the Phase 2 study by Frias et al., 2023 provides data on the combination in a diabetes model. This makes the amylin principle the most recent building block of multi-pathway research and the query amylin analogue weight loss a field in its own right.

What trial data exist for the individual peptides?

The direct research comparison of the four substance classes makes the systematics visible. All the following values derive from placebo-controlled clinical trials with 48 to 72 weeks of observation and describe the mean weight change of the respective drug candidates.

| Substance | Receptor profile | Trial | Weight change | Placebo | | --- | --- | --- | --- | --- | | Retatrutide | GIP/GLP-1/glucagon | Phase 2 (48 wk) | -8.7 to -24.2 % | -2.1 % | | Tirzepatide | GIP/GLP-1 | SURMOUNT-1 (72 wk) | -16.0 to -22.5 % | -3.1 % | | Semaglutide | GLP-1 | STEP 1 (68 wk) | -14.9 % | -2.4 % | | Cagrilintide + semaglutide | Amylin + GLP-1 | Phase 1b (20 wk) | -15.7 to -17.1 % | -9.8 %* | | CagriSema | Amylin + GLP-1 | REDEFINE 1 (68 wk) | -20.4 % | -3.0 % |

*Comparator arm semaglutide alone.

The systematics reveal a consistent research trend: with each additional receptor addressed, the magnitude of reported weight reduction rises in these models. The triple agonist retatrutide marks the highest single value in the Phase 2 analysis by Jastreboff et al., 2023. At the same time, the trials differ in duration, participant number, and study phase, which is why a direct numerical comparison must always account for these methodological conditions. A further data comparison is available at Retatrutide vs. CJC-1295.

What pharmacokinetic properties distinguish the peptides?

Pharmacokinetics determines the dosing interval of the trial protocols in research. All four lead substances show a terminal half-life in the range of several days and were administered subcutaneously at weekly intervals in trials.

For retatrutide, Urva et al., 2022 reported in the first-in-human study a terminal half-life of about 5 to 7 days, corresponding to roughly 144 to 165 hours, with a maximum plasma concentration after about 1 to 3 days and dose-proportional kinetics. The stated biological half-life is around 6 days. Semaglutide shows a comparable half-life at around 7 days (about 165 hours), which in both cases supports the weekly interval.

Tirzepatide sits slightly below at around 5 days (about 117 hours), while cagrilintide as a long-acting amylin analogue shows the longest half-life of the group at around 7 to 9 days. This kinetic profile explains why the combination of cagrilintide and semaglutide is pharmacologically well matched. For the precise conversion of half-life, steady-state, and accumulation factor, the Peptide Calculator provides a pharmacokinetic tool that models the values named here.

What molecular weights and structures do these peptides have?

Molecular structure explains the pharmacological differences between the peptides. Retatrutide is a 30 amino-acid peptide with a C18 diacid modification and an amidated C-terminus. The sequence given in the product data sheet begins with His and ends on Gly-Arg-NH2; the fatty-acid modification extends the plasma half-life through albumin binding, an established principle in peptide chemistry.

The approximate molecular weights of the four lead substances lie close together but differ characteristically:

| Substance | Molecular formula (approx.) | Molecular weight (approx.) | | --- | --- | --- | | Semaglutide | C187H291N45O59 | 4113.6 g/mol | | Cagrilintide | Amylin analogue | 3751.9 g/mol | | Retatrutide | 30-mer, C18 diacid | approx. 4731 g/mol | | Tirzepatide | C225H348N48O68 | 4813.5 g/mol |

These values are approximations and should be checked against a chemistry database before analytical use. Notably, cagrilintide as an amylin analogue is the smallest molecule of the group, while the dual agonist tirzepatide is the largest. Retatrutide, despite its three receptor targets, sits in the middle range, showing that receptor selectivity does not depend on molecular size alone but on the exact amino-acid sequence and chemical modifications. Coskun et al. described the receptor-potency profiles across all three target receptors in detail.

Which doses are used in studies?

The doses reported in the literature serve only to describe the trial protocols and do not constitute a use recommendation. All named substances are research peptides; a transfer of the study doses to a use context outside controlled research does not take place in this guide.

In the retatrutide trials, a dose range of 1 to 12 mg per week subcutaneously was studied. To improve tolerability, the trial protocols used a stepwise dose escalation of 2 or 4 mg every four weeks, as Jastreboff et al., 2023 described. This slow up-titration is a recurring feature of incretin research and serves to reduce gastrointestinal effects.

For comparison, the reference trials studied tirzepatide at doses of 5, 10, and 15 mg weekly, semaglutide at 2.4 mg weekly, and cagrilintide at doses up to 2.4 mg weekly.

What are the best peptides for fat burning in research comparison?

The question of the best peptides for fat burning can be answered in research comparison only through the receptor profile and the composition of the weight loss, not through blanket rankings. What matters in research is which share of the weight reduction actually falls on fat mass rather than lean mass.

Here SURMOUNT-1 provides the most precise dataset: Jastreboff et al., 2022 reported for tirzepatide a roughly threefold greater reduction in fat mass versus lean mass (33.9 percent to 10.9 percent). Retatrutide complements this profile with the glucagon component, which according to Coskun et al., 2022 raises hepatic lipid oxidation and basal energy expenditure, establishing a direct link to fat burning in liver tissue. The reported liver-fat reduction of roughly 86 percent under 12 mg retatrutide underscores this aspect.

For pure satiety effect, the amylin pathway is relevant, while GLP-1 slows gastric emptying. In research terms, there is therefore no single best peptide, but complementary receptor strategies. The triple agonist retatrutide combines most of these mechanisms in one molecule and is therefore of particular interest in current obesity research.

These trial results relate exclusively to the drug candidate under clinical investigation; they are not a promise of benefit and not a reason to buy.

Order Retatrutide now

How are these research peptides stored and reconstituted?

Correct storage is decisive for the stability of the peptides. Retatrutide is supplied as a lyophilized, temperature-stable powder. In the freeze-dried state, the peptide is comparatively robust but should nonetheless be kept cool, dry, and protected from light to avoid degradation of the amino-acid sequence.

After reconstitution with bacteriostatic water, the requirement profile changes markedly. The dissolved substance should be stored refrigerated at about 2 to 8 degrees Celsius, since dissolved peptides in aqueous solution are considerably more susceptible to hydrolytic and microbial breakdown. Bacteriostatic water contains benzyl alcohol, which inhibits the growth of microorganisms over several weeks and is therefore regarded as the standard reconstitution medium in peptide research.

Repeated freezing and thawing should be avoided, since temperature cycles can impair the three-dimensional structure of the peptide. For quality assurance, the material described here is mass-spectrometry confirmed, tested by HPLC to a purity of at least 99 percent, and screened for endotoxins. This analytics is a prerequisite for reproducible results in research. The long biological half-life of around 6 days is a property of the molecule in the organism and must not be confused with the shelf stability of the reconstituted solution, which is considerably shorter.

What side effects are known from research?

In the clinical trials of the incretin class, gastrointestinal effects occurred most frequently. These included nausea, vomiting, diarrhea, and constipation, and were generally dose-dependent and most pronounced in the first weeks of dose escalation. For this reason, the trial protocols used the stepwise up-titration already described to improve tolerability.

For retatrutide, Jastreboff et al., 2023 reported a side-effect profile comparable to that of the other incretin agonists, with gastrointestinal effects increasing at higher doses. The additional glucagon component of the triple agonist was the subject of separate monitoring of heart rate and glucose metabolism in the trials, since glucagon-receptor activation can influence these parameters.

For the dual and mono-agonists, SURMOUNT-1 (Jastreboff et al., 2022) and STEP 1 (Wilding et al., 2021) showed a consistent picture with predominantly mild to moderate gastrointestinal events. For the amylin combination, Enebo et al., 2021 described a similar tolerability pattern. All these observations derive from controlled trials on the drug candidates and describe only findings within the trial context, not experiences from use outside research.

Frequently Asked Questions

Are peptides for weight loss the same as approved medicines?

No. The substances described here are research peptides and are offered exclusively as lyophilized laboratory material for research purposes. The cited trial data refer to the pharmacological characterization of the drug candidates and not to any use outside controlled research.

How does retatrutide differ from tirzepatide?

Retatrutide is a triple agonist that binds GIP, GLP-1, and the glucagon receptor, while tirzepatide as a dual agonist addresses only GIP and GLP-1. The additional glucagon component is associated in research with increased energy expenditure and hepatic lipid oxidation. A structured data comparison is offered at Retatrutide vs. Tirzepatide.

What does an amylin analogue mean compared with GLP-1?

An amylin analogue such as cagrilintide acts through its own receptor, mediating satiety and gastric emptying independently of the GLP-1 pathway. The Phase 1b trial by Enebo et al. showed that amylin and GLP-1 action behave additively in the reported data.

How long is the half-life of retatrutide?

In the first-in-human study by Urva et al., a terminal half-life of about 5 to 7 days was reported, corresponding to roughly 144 to 165 hours. The precise modeling of steady-state and accumulation can be traced with the Peptide Calculator.

How are reconstituted peptides stored?

After dissolving with bacteriostatic water, the peptides should be stored refrigerated at about 2 to 8 degrees Celsius and protected from repeated freezing. The lyophilized powder itself is temperature-stable but should likewise be kept cool and protected from light.

For research purposes only. Not intended for human consumption. Scientific editor: Dr. Sieglinde Klaus